AMEX:CANF   CAN FITE BIOPHARMA LTD SPON ADS EA REP 30 ORD SHS(POST REV SPL
Recent Highlights:

1. Can-Fite announced that due to patient survival, top-line results of the Namodenoson Phase II advanced liver cancer study were expected to be
released in Q1 2019. The statistical plan for this trial requires that the primary efficacy analysis occurs when no more than 3 of the original 78
patients survive. it means, approximately 2 months for results

2. In anticipation of the Phase II liver cancer data release, Can-Fite brought on board Professor Joseph Llovet, a Key Opinion Leader in the field of
liver diseases, founder and director of the Liver Cancer Program and full professor of medicine at the Mount Sinai School of Medicine, New
York University (USA). Professor Llovet will assist in the analysis of the Phase II data that are anticipated in Q1 2019.

3. January 18, 2019 , offered 4,476,192 ordinary shares represented by 2,238,096 American Depositary Shares, or ADSs, to an institutional investor under a
securities purchase agreement.

With two top-line data expected in Q1/2019 and H1/2019 for HCC and NAFLD/NASH, respectively, 2019 will be an awakening year.

Technically, a good things can happen only above MA200 and 1.35.
But how CANF will behave from now to that critical results of PH2?

Follow RSI and MACD :)

I do not recommend selling or buying,
Holding CANF
首頁 股票篩選器 外匯篩選器 加密貨幣篩選器 全球財經日曆 如何運作 圖表功能 價格 網站規則 版主 網站 & 經紀商解決方案 小工具 圖表解決方案 尋求幫助 功能請求 部落格 & 新聞 常見問題 維基 推特
概述 個人資料設定 賬戶和賬單 尋求幫助 發表的想法 粉絲 正在關注 私人訊息 在線聊天 登出